Ignite Creation Date:
2025-12-24 @ 6:27 PM
Ignite Modification Date:
2025-12-31 @ 7:18 AM
Study NCT ID:
NCT04607668
Status:
TERMINATED
Last Update Posted:
2024-11-26
First Post:
2020-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Sponsor:
G1 Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-06
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-31
Completion Date Type:
ACTUAL
First Submit Date:
2020-10-20
First Submit QC Date:
None
Study First Post Date:
2020-10-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-05-16
Results First Submit QC Date:
None
Results First Post Date:
2024-11-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-18
Last Update Post Date:
2024-11-26
Last Update Post Date Type:
ACTUAL